Business Description
Allarity Therapeutics Inc
NAICS : 541714
SIC : 2833
ISIN : US0167445008
Total Employee Number:
8Description
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.92 | |||||
Equity-to-Asset | 0.2 | |||||
Debt-to-Equity | 3.11 | |||||
Debt-to-EBITDA | -1.98 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -5.73 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 96.5 | |||||
3-Year EPS without NRI Growth Rate | 97 | |||||
3-Year FCF Growth Rate | 96.1 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 33.37 | |||||
9-Day RSI | 34 | |||||
14-Day RSI | 37.05 | |||||
3-1 Month Momentum % | 17.32 | |||||
6-1 Month Momentum % | 27.35 | |||||
12-1 Month Momentum % | 37.96 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.23 | |||||
Quick Ratio | 1.23 | |||||
Cash Ratio | 0.71 | |||||
Days Sales Outstanding | 1498.09 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2424.1 | |||||
Shareholder Yield % | -23.28 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -3552.75 | |||||
Net Margin % | -3260.58 | |||||
EBITDA Margin % | -3151.3 | |||||
FCF Margin % | -4837.97 | |||||
OCF Margin % | -4819.42 | |||||
ROE % | -94.38 | |||||
ROA % | -45.03 | |||||
ROIC % | -213.28 | |||||
3-Year ROIIC % | -25.99 | |||||
ROC (Joel Greenblatt) % | -618.02 | |||||
ROCE % | -91.38 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 52.95 | |||||
PB Ratio | 2.67 | |||||
Price-to-Tangible-Book | 2.65 | |||||
EV-to-EBIT | -1.86 | |||||
EV-to-EBITDA | -1.86 | |||||
EV-to-Revenue | 58.61 | |||||
EV-to-Forward-Revenue | 808.8 | |||||
EV-to-FCF | -1.21 | |||||
| Price-to-Net-Current-Asset-Value | 2.84 | |||||
Earnings Yield (Greenblatt) % | -53.76 | |||||
FCF Yield % | -90.05 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ALLR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Allarity Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.345 | ||
| EPS (TTM) ($) | -0.72 | ||
| Beta | 0.984 | ||
| 3-Year Sharpe Ratio | -1.72 | ||
| 3-Year Sortino Ratio | -1.68 | ||
| Volatility % | 69.74 | ||
| 14-Day RSI | 37.05 | ||
| 14-Day ATR ($) | 0.117965 | ||
| 20-Day SMA ($) | 1.31475 | ||
| 12-1 Month Momentum % | 37.96 | ||
| 52-Week Range ($) | 0.7687 - 2.35 | ||
| Shares Outstanding (Mil) | 15.91 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Allarity Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Allarity Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 124 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 33 days | ||
| General meeting for 2026 | 2026-06-26 10:00 | 1.27 (-2.31%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 1.51 (-2.58%) | ||
| Annual report for 2025 | 2026-03-30 | 1.07 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 1.19 (-6.30%) | ||
| Second quarter earnings results for 2025 | 2025-08-15 | 0.98 (-2.02%) | ||
| General meeting for 2025 | 2025-06-13 13:00 | 0.84 (-5.30%) | ||
| First quarter earnings results for 2025 | 2025-05-09 | 1.07 (+2.88%) | ||
| Annual report for 2024 | 2025-03-31 | 1.04 (+1.96%) |
Show
Entries
Allarity Therapeutics Inc Frequently Asked Questions
What is Allarity Therapeutics Inc(ALLR)'s stock price today?
The current price of ALLR is $1.17. The 52 week high of ALLR is $2.35 and 52 week low is $0.77.
When is next earnings date of Allarity Therapeutics Inc(ALLR)?
The next earnings date of Allarity Therapeutics Inc(ALLR) is 2026-08-14 Est..
Does Allarity Therapeutics Inc(ALLR) pay dividends? If so, how much?
Allarity Therapeutics Inc(ALLR) does not pay dividend.
Guru Commentaries on NAS:ALLR
No articles.
Press Release
Articles on Allarity Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers